Clear cell renal cell carcinoma
Not recruitingStudy on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer
Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer
- Disease:Clear cell renal cell carcinoma
- Substances:IpilimumabNivolumab+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting










